EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico
Compare the costs effectiveness of RVd (lenalidomide, bortezomib and dexamethasone) and D-VTd (daratumumab, bortezomib, thalidomide and dexamethasone) as induction regimen prior to autologous stem cell transplantation (ASCT) and estimate the budget impact associated with the use of RVd in this indication, from the perspective of the public health sector in Mexico.
Source: Value in Health - Category: International Medicine & Public Health Authors: R. Romero, V. Mena Source Type: research
More News: Budgets | Dexamethasone | International Medicine & Public Health | Men | Mexico Health | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants | Velcade